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Abstract	
Neural signals along the vagus nerve (VN) drive many somatic and autonomic functions. The 
clinical interest of VN stimulation (VNS) is thus potentially huge and has already been 
demonstrated in epilepsy. However, side effects are often elicited, in addition to the targeted 
neuromodulation. This review examines the state of the art of VNS applied to two emerging 
modulations of autonomic function: heart failure and obesity, especially morbid obesity. We 
report that VNS may benefit from improved stimulation delivery using very advanced 
technologies. However, most of the results from fundamental animal studies still need to be 
demonstrated in humans. 
 
Keywords: Vagus nerve stimulation (VNS), Heart failure, Obesity, Gastrointestinal disorders, 
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 1	Introduction	
 
The vagus nerve (VN), also called the pneumogastric nerve, is the tenth pair (X) and the longest 
of the cranial nerves. The VN is a component of the autonomic nervous system (ANS), more 
specifically of the parasympathetic nervous system, and it innervates various organs, including 
the heart and digestive system. It also acts on somatic functions, such as those linked to speech. 
At the cervical level in humans, each trunk (right and left) contains nearly 100,000 afferent and 
efferent fibers, about 80% and 20%, respectively (Foley and DuBois 1937 cited by (George et al., 
2000)). The VN is composed of A, B and C fibers (Bailey and Bremer, 1938, cited by (Groves 
and Brown, 2005, Castoro et al., 2011)), which are characterized by decreasing diameters and 
velocities and increasing stimulation thresholds (Erlanger and Gasser, 1930 cited by (Duclaux et 
al., 1976)). Recently, it was shown in humans that the VN comprises around 5% sympathetic 
fibers (Seki et al., 2014) and that the mean effective surface area of the right VN is higher than 
that of the left (Verlinden et al., 2016). Regarding the distribution of VN termination in the heart, 
the following has been shown: 1) parasympathetic innervation is higher in the atrium than in the 
ventricle (Kawano et al., 2003); 2) the right atrium is more innervated than the left (Ulphani et 
al., 2010), and 3) the right ventricle is more innervated than the left (Ulphani et al., 2010). In their 
seminal publication, Cohn and Lewis (Cohn and Lewis, 1913) proposed that the right VN mostly 
innervates the sinoatrial node, whereas the left VN predominantly innervates the atrioventricular 
node, although this hypothesis was not confirmed by preclinical studies (Hamlin and Smith, 
1968, Randall and Armour, 1974). Using vagus nerve stimulation (VNS) on both sides, it was 
demonstrated that right and left VNS have the same effect on heart rate, left ventricular pressure 
and contractility (Yamakawa et al., 2015). 
 
VNS was first described by Corning (Corning, 1883), who suggested that the seizures of epilepsy 
could be suppressed by lowering the heart rate. In 1938, Bailey and Bremer demonstrated the 
direct effect of VNS on central nervous functions (Bailey and Bremer, 1938). MacLean and 
Pribram then reported in 1949 that VNS induced slow waves over the lateral frontal cortex (cited 
by (George and Aston-Jones, 2010)), and two years later Dell and Olson determined that 
proximal stimulation of the VN evoked responses in the ventroposterior complex and 
intralaminar regions of the thalamus (Dell and Olson, 1951). In 1952, Zanchetti et al. 
demonstrated that VNS suppresses the interictal epileptic events in a cat model (Zanchetti et al., 
1952). These preliminary studies thus opened the way to using VNS as a therapeutic option in the 
treatment of epilepsy. In 1985, Zabara described for the first time the effect of VNS on seizure 
control in a canine model (Zabara, 1985). This study has since been confirmed and 
complemented by the findings of several authors (Lockard et al., 1990, Woodbury and 
Woodbury, 1990, McLachlan, 1993). 
 
Given this history, we can easily understand the interest of stimulating the VN using implantable 
devices to modulate essential functions. Yet, although stimulation of peripheral nerves is now a 
well-known concept, the richness and complexity of the information transmitted along the VN 
raises serious challenges that have thus far hampered the more rapid and widespread use of VNS. 
Intensive research has nevertheless been ongoing for the same reasons. 
 
VNS was successfully used to treat epilepsy with an implantable neurostimulator, and this is by 
far its most extensive application. The first study in humans was published in 1990 (Penry and 
Dean, 1990) in a small series of patients. The first international study with a larger population 
was published in 1994 (Ben-Menachem et al., 1994), and it confirmed the effectiveness of VNS 
in the epilepsy treatment. An earlier review {Binnie, 2000) reported the clear benefits of VNS, 
with a significant reduction in seizure frequency. However, the percentage of patients for which 
VNS is very efficient (number of seizures reduced by >50%) remains under one third and the 
placebo effect was not clearly assessed in the above-mentioned studies. Side effects such as pain, 
voice changes and coughing have been reported as limitations to the possible efficacy of VNS 
and therefore, to avoid these adverse effects, stimulation intensity cannot be increased up to a 
level for which a positive effect is obtained. In a long-term study of patients followed for more 
than ten years (Elliott et al., 2011), the authors observed significant seizure reduction, with an 
increasing effect over time: >75% at 10 years). 
The present review will focus on two promising therapeutic application of VNS: heart failure and 
obesity; nevertheless, VNS has been studied in many other clinical applications: 
• depression (Rush et al., 2000, Goodnick et al., 2001, Sackeim et al., 2001, Lomarev et al., 
2002, Mu et al., 2004, Rush et al., 2005a, Rush et al., 2005b, George et al., 2005, Nahas et 
al., 2005, Bodenlos et al., 2007, Labiner and Ahern, 2007, Daban et al., 2008, Milby et al., 
2008, Schlaepfer et al., 2008, Bajbouj et al., 2010, Sperling et al., 2010, Aaronson et al., 
2013, Conway et al., 2013, Feldman et al., 2013, Landau et al., 2015, Grimonprez et al., 
2015); 
• inflammation and autoimmune diseases (Borovikova et al., 2000, van Westerloo et al., 
2006, Barone et al., 2007, Zitnik, 2011, Kox et al., 2012, Mihaylova et al., 2012, Bonaz et 
al., 2013, Levine et al., 2014, Yamakawa et al., 2013, Didier et al., 2014, Pellissier et al., 
2014, Li et al., 2015, Bonaz et al., 2016); 
• cognition and brain injury (Masada et al., 1996, Clark et al., 1999, George et al., 2000, 
Furmaga et al., 2012, Lopez et al., 2012, Mihaylova et al., 2012, Sun et al., 2012, 
Khodaparast et al., 2013, Yamakawa et al., 2013, Vonck et al., 2014, Hays et al., 2014, 
Ay et al., 2014, Cai et al., 2014, Jiang et al., 2014, Pena et al., 2014, Chunchai et al., 
2015, Neren et al., 2015, Dawson et al., 2016); 
• arrhythmias (Kolman et al., 1975, Zuanetti et al., 1987, Vanoli et al., 1991, Murakawa et 
al., 2003, Zheng et al., 2005, Brack et al., 2007, Ng et al., 2007, Li et al., 2009, Zhang et 
al., 2009a, Shen et al., 2011, Brack et al., 2011, Yu et al., 2011, Shinlapawittayatorn et al., 
2013, Stavrakis et al., 2013, Huang et al., 2014, Annoni et al., 2015, Huang et al., 2015, 
Stavrakis et al., 2015, Zhang et al., 2015a, Zhang et al., 2016); 
• ischemia and myocardial infarction (Kent et al., 1973, Myers et al., 1974, Sneddon et al., 
1993, Zamotrinsky et al., 2001, Li et al., 2005, Katare and Sato, 2007, Del Rio et al., 
2008, Katare et al., 2010, Uemura et al., 2010, Calvillo et al., 2011, Wu and Lu, 2011, 
Kong et al., 2012, Shinlapawittayatorn et al., 2013, Beaumont et al., 2015, Chen et al., 
2015, Uitterdijk et al., 2015 , Zhang et al., 2015b); 
• anxiety (Rush et al., 2005a, Chavel et al., 2003, Childs et al., 2015);  
• pain (Kirchner et al., 2000, Kirchner et al., 2006, De Couck et al., 2014 , Chakravarthy et 
al., 2015); 
• hypertension (Gierthmuehlen and Plachta, 2015, Annoni et al., 2015); 
• migraines and headache (Hord et al., 2003). 
	The remainder of the paper will nevertheless concentrate on cardiac and digestive clinical 
applications. The paper first presents the known VNS mechanisms on the targeted pathologies. 
The state of the art of the technologies involved in VNS and the clinical results are then 
presented, followed by a review of the recent research that suggests new stimulation paradigms. 
2	Anatomy	and	physiology	of	the	autonomic	functions	
 
2.1	Cardiac	function	
 
In normal cardiac function, the adapted amount of blood is continuously carrying to the entire 
organism, according to organ needs. In response to physical and physiological modifications, the 
heart adapts its strength, power and speed, as does the peripheral vascular system, which can 
contract and expand. Thereby, the heart controls its rate and contractility. Heart failure (HF) can 
be defined in different ways depending on whether one takes the pathophysiological or clinical 
perspective. Pathophysiologically, the structure or function of the heart is abnormal, leading to 
the inability of the cardiac pump to ensure sufficient blood flow to meet the body’s metabolic 
needs under normal conditions. Clinically, HF is a syndrome combining functional (asthenia, 
dyspnea) and physical (crackles, lower limb edema, jugular turgor, hepatojugular reflux) signs. 
The European Society of Cardiology defines it thusly: “Heart failure as a clinical syndrome in 
which patients have typical symptoms and signs resulting from an abnormality of cardiac 
structure and function” (McMurray et al., 2012). 
In the general adult population in Western countries, HF prevalence is estimated to be between 1 
and 2% (Parameshwar et al., 1992, McDonagh et al., 1997, Davies et al., 2001, Murphy et al., 
2004). In the aged population (Tiller et al., 2013), the overall prevalence is 7.7% for men and 
9.0% for women, with the prevalence (Eriksson et al., 1989, Kupari et al., 1997, Mosterd et al., 
1999, Morgan et al., 1999, Vaes et al., 2012) and incidence increasing significantly with age 
(Cowie et al., 1999, Murphy et al., 2004). 
It is well known that the heart is under the control of both sympathetic and parasympathetic 
nervous systems (Levy, 1971), leading to the concept of “autonomic balance.” Stimulation of the 
sympathetic nervous system increases heart rate, blood pressure and myocardial inotropism, 
while stimulation of the parasympathetic nervous system reduces heart rate, blood pressure, and 
contractility. Both systems act to regulate heart rate, blood pressure, cardiac structure and 
function, and the electrical stability of the myocardium. Autonomic imbalance, characterized by 
decreased vagal (parasympathetic) activity and increased sympathetic activity, correlates with 
cardiovascular diseases such as HF, arrhythmias, ischemia/reperfusion injury and hypertension. 
In HF, decreased cardiac output leads to compensatory mechanisms, particularly activation of the 
renin-angiotensin-aldosterone system (RAAS) (Bristow, 1984) and the sympathetic nervous 
system, through afferent stimuli from the baroreceptors to the central nervous system 
cardioregulatory centers (Parati and Esler, 2012). These compensatory mechanisms initially help 
maintain cardiac output but are detrimental over the long term through reduced cardiac 
sympathetic neuronal density and responsiveness, increased vasoconstrictor tone, and further 
activation of the RAAS and the endothelin 1 and vasopressin systems, which may be responsible 
for peripheral organ dysfunction and damage (Floras, 2009). Increased sympathetic activity, 
besides being proarrhythmic, is also associated with nitric oxide deregulation, increased 
inflammation with excess cytokine release and adverse ventricular remodeling (Ogawa et al., 
2007, Li and Olshansky, 2011). Experimental (Billman et al., 1982, Vanoli et al., 1991) and 
clinical (La Rovere et al., 1998) works have also shown that (i) depressed vagal reflexes – 
measured via baroreflex sensitivity (BRS) and heart rate variability (HRV) – are strongly 
associated with susceptibility to ventricular arrhythmias in the early postinfarction period and (ii) 
depressed BRS in patients with HF with reduced left ventricular ejection fraction (LVEF) 
identifies those at high risk for cardiac and arrhythmic mortality (Billman et al., 1982, La Rovere 
et al., 1998). Moreover, sympathetic nerve hyperactivity was shown to be related to impaired 
cardiac performance in patients with HF (Ferguson et al., 1990). In a large clinical study, Mortara 
et al. demonstrated that in HF patients with reduced LVEF, the BRS is reduced in parallel with 
the clinical and hemodynamic status (Mortara et al., 1997). These findings have led to the 
hypothesis that VNS may offer an opportunity to regulate the “sympatovagal balance”. 
 
The aims of HF treatment are to control symptoms and improve functional capacity, reduce 
hospitalizations and decrease mortality. The therapeutic strategies were established by the 
European Society of Cardiology (McMurray et al., 2012), and they consist of single or combined 
pharmacological approaches: diuretics (Marvin, 1927), beta-blockers and ACE inhibitors 
(angiotensin-converting-enzyme) (Ho et al., 2014), Ivabradine to reduce heart rate (Fox et al., 
2008, Swedberg et al., 2010) or a combination of molecules (McMurray et al., 2014). 
In certain cases, defined by the European society of cardiology (McMurray et al., 2012), the 
pharmaceutical treatment can be completed by the implantation of a medical device, such as an 
implantable cardioverter/defibrillator (CONSENSUS investigators, 1987, AVID investigators, 
1997, Kadish et al., 2004) or a cardiac resynchronization device (Cazeau et al., 2001, Bristow et 
al., 2004, Moss et al., 2009, Linde et al., 2010, Tang et al., 2010, Bogale et al., 2012, McMurray 
et al., 2012, Brignole et al., 2013). 
For patients with end-stage HF, the conventional therapeutic solutions are limited to cardiac 
transplantation or a left ventricular assist device (McMurray et al., 2012). The implantable 
artificial heart is a new emergent opportunity (Copeland et al., 2004, Tarzia et al., 2014, 
Latremouille et al., 2015). 
 
2.2	Weight	control	
 
The central nervous system (CNS) controls eating behavior and energy regulation. New, well-
tolerated and effective therapies are needed to help curb the growing obesity epidemic. Ongoing 
research and a deepening understanding of the relationship between the gastrointestinal tract and 
the brain in the control of eating behavior, as well as electrical stimulation as a therapy, have 
helped open new “windows” for developing long-lasting and safe obesity treatment. Indeed, a 
new approach to obesity treatment that is currently being tested focuses on its effect on the 
interaction between the CNS and the gastrointestinal tract. This interaction is mainly handled by 
the VN (Roslin and Kurian, 2001), which has a role in linking the brain and the gut for 
bidirectional communication. It has been shown that afferent neurons of the VN propagate 
information to the brain on the control of food intake and thus feed homeostasis (Bray, 2000, 
Ziomber et al., 2009). In non-obese individuals, chemo- and mechanosensory vagal receptors 
signal the immediate availability of food to the brain. This signaling is altered in the obese as a 
consequence of the reduced sensitivity of small intestinal afferents. Since chronic VNS has the 
potential to restore this missing or altered signaling, it might be an effective treatment for obesity. 
Using the pig as a preclinical model, Val-Laillet used juxta-abdominal bilateral VNS in the 
longest longitudinal study performed to date (Val-Laillet et al., 2010a). They showed that VNS 
decreased weight gain, food consumption and sweet craving in adult obese minipigs. However, 
the long delay observed between the onset of stimulation and the appearance of beneficial effects 
exemplifies our current inability to fully understand the brain mechanisms involved by VNS. 
To further understand the intricacies of VNS effects on food intake, brain functional imaging in a 
large animal model cab has helped to identify the brain networks affected by VNS. Early studies 
on brain activation after juxta-abdominal bilateral VNS performed in growing pigs using single-
photon gamma scintigraphy evaluated the VNS effect on non-pathologic brain (Biraben et al., 
2005, Biraben et al., 2008). They showed the activation of two networks: (i) the first is associated 
with the olfactory bulb and primary olfactory projections areas, and (ii) the second involves areas 
already demonstrated as essential to integrate gastroduodenal mechanosensory information 
(hippocampus, pallidum) so as to give hedonic valance to them. More recently, our group used 
PET FDG imaging to evaluate the potential changes in glucose metabolism induced in the brain 
by VNS. Unlike behavioral effects that take several weeks to be identified, modifications in 
glucose metabolism, which reflects brain activity, were present one week after the onset of VNS 
therapy. The following brain areas presented significant differences compared with the effects of 
sham stimulation: cingular cortex, putamen, caudate nucleus and the substancia nigra/tegmental 
ventral area. Interestingly, these areas are part of the main mesolimbic dopaminergic reward 
network (Malbert, 2013). The massive activation of the reward network at an early stage of 
chronic stimulation suggests that brain imaging might be a tool to optimize the VNS parameters 
and/or that part of the effect on body weight might relate to the involvement of the reward 
network. 
3	Current	approaches	
 
3.1	Existing	implantable	devices	for	HF	
 
In an experimental study, Myers et al. showed that VNS reduces the incidence of spontaneous 
ventricular fibrillation (Myers et al., 1974). These findings were confirmed by Vanoli et al. 
(Vanoli et al., 1991) in acute ischemic episodes in dogs. More recently, VNS has been evaluated 
in animal models with HF with reduced LVEF (Li et al., 2004, Sunagawa, 2005, Sabbah et al., 
2007, Zhang et al., 2009b). VNS devices have also been implanted and evaluated in humans 
(Table 1). In a small series, the first human experiment on VNS to treat HF (Schwartz et al., 
2008) showed that NYHA class and quality of life (QOL) were significantly improved. Table 1 
summarizes the preliminary data demonstrating the safety of direct VNS in HF patients with low 
LVEF. These data suggest significant improvement in the subjective and objective endpoints of 
HF, although the results need to be confirmed in larger multicenter randomized studies focused 
on morbidity and mortality data. The benefits may be mediated by slower heart rate, blunting of 
the sympathetic activity, inhibition or down-regulation of the RAAS, and enhanced signaling 
pathways, which facilitate restoration of the BRS, suppression of the proinflammatory cytokines, 
and suppression of gap junction remodeling (Sabbah et al., 2011). However, the authors of the 
NECTAR-HF study, for example, hypothesized that the placebo effect is partly responsible for 
these results, as blinding has not yet been reached. Another explanation may be related to the 
titration process, which is limited by patients’ side effects. The mean current applied in the study 
was considerably less than in a previous study (4.1 ± 1.2 mA) (Kuck et al., 2014). This last study 
in particular confirms that managing the side effects induced by VNS at the cervical level is a key 
point for the future development of this therapy. Suggested major contributing mechanisms are 
listed in Table 2. 
 
Study Stimulation paradigm / study design Main results 
CardioFit system BioControl Medical Ltd 
(Yehudi, Israel) 
Preliminary study 
(Schwartz et al., 2008) 
(De Ferrari et al., 2011) 
 
INOVATE-HF study 
(Gold et al., 2016) 
Asymmetric bipolar multi-contact cuff 
electrode designed to preferentially activate 
the efferent B fibers in the right cervical VN. 
Synchronous VNS on cardiac events, one or 
two pulses are delivered by cardiac cycle. 
Right ventricular sensing electrode to prevent 
excessive bradycardia from VNS (Anholt et 
al., 2011). 
A preliminary study involved 8 patients in a 
first step and 32 patients in a second step. It 
was a non controlled and non randomized 
study. 
The INOVATE-HF was a randomized and 
controlled study. It involved 707 patients in a 
3:2 ration (implanted device vs. standard 
medical therapy). The mean current was 3.9 ± 
1.0 mA. No data were published on the 
number of pulses per cardiac cycle. 
In preliminary study, HF with reduced LVEF 
showed that hemodynamic performances 
were significantly improved by VNS. Results 
were confirmed by an open-label multi-centre 
pilot study in 32 patients with NYHA class 
II–IV and LVEF<35%, which demonstrated 
the positive impact of VNS on structural and 
functional endpoints. A substantial proportion 
of patients improved their NYHA class and 6-
min walk test, with an improvement in LVEF 
and QoL. 
INOVATE-HF failed to demonstrate a benefit 
on cardiac parameters. 
Boston Scientific Corporation (Marlborough, 
MA, USA) 
NECTAR-HF 
(Zannad et al., 2015) 
The electrode is a bipolar helical system. 
The VNS was delivered asynchronously at 20 
Hz. 
 
2:1 randomized sham-controlled trial in 96 
NYHA II/III patients with LVEF < 35%. 
Mean current applied 1.4 ± 0.8 mA. 
The study failed to demonstrate at 6 months a 
favorable effect of direct right VNS (versus 
VNS OFF) on left ventricular end systolic 
diameter (LVESD) (primary endpoint). 
No benefit on left ventricular end diastolic 
dimension and volume, left ventricular end 
systolic volume and ejection fraction, peak 
VO2 and NT-proBNP. 
An improvement demonstrated in subjective 
parameters such as NYHA class and QoL.  
Cyberonics (Houston, USA) 
ANTHEM-HF 
(Premchand et al., 2014) 
ENCORE 
(Premchand et al., 2015) 
The electrode is a bipolar helical system. 
The VNS was delivered asynchronously at 10 
Hz. 
 
Comparison of right versus left cervical VNS 
60 patients, without control group. 
No difference between these 2 configurations. 
Improvement of LVEF at 6 months compared 
to baseline. 
In the ENCORE study, a subgroup of 49 
patients from ANTHEM-HF, it has been 
shown that the improvement in cardiac 
function and HF symptoms were maintained 
at 12 months 
Table 1: summary of clinical studies. QoL: quality of life; LEVF: left ventricular ejection 
fraction; NYHA class: New-York Heart Association classification 
 
Effect Publication Main results 
Antiarrhythmic effects at the ventricular level (Prystowsky et al., 1981) 
(Litovsky and Antzelevitch, 1990) 
(Vanoli et al., 1991) 
(Li et al., 2004) 
(Zheng et al., 2005) 
(Ng et al., 2007) 
(Kuck et al., 2014) 
VNS increases the ventricular refractory 
period in humans. It leads to a prolongation of 
the epicardial action potential duration and 
decreases vulnerability to ventricular 
fibrillation. Its antifibrillatory effects was 
demonstrated in post-infarction animal 
models; VNS decreases sudden cardiac death 
in dogs with a healed myocardial infarction. 
In a rat model of myocardial infarction-
induced HF, VNS significantly reduced 
arrhythmias and increased long-term survival. 
It prevents the loss of connexin-43 induced by 
ischemia, improving electrical stability. 
Rate slowing effects (Bohm et al., 2010) VNS exerts deep negative chronotropic and 
dromotropic effects. A reduction of heart rate 
might contribute to beneficial therapeutic 
effects in HF. 
Antifibrotic effects (Zhang et al., 2009b) It shows that VNS decreases ventricular 
replacement fibrosis and blunts the 
development of HF-associated cellular 
hypertrophy of remaining myocytes in a 
coronary microembolization-induced HF. 
Anti-inflammatory effects (Borovikova et al., 2000) 
(Zhang et al., 2009b) 
(Hamann et al., 2013) 
  
VNS anti-inflammatory effects was shown to 
blunt HF-associated increases of TNF-α, IL-6 
and CRP in two animal models of HF. 
Reverse remodeling (Li et al., 2004) 
(Zhang et al., 2009b) 
(Hamann et al., 2013) 
VNS decreases LV end-systolic and end-
diastolic diameters, improves LVEF reduces 
NT-proBNP levels in a dog HF model and 
biventricular weight in a rat HF model. 
Antiarrhythmic effects at the atrial level (Li et al., 2009) 
(Yu et al., 2011) 
(Chen et al., 2014) 
Autonomic nerve activity may contribute to 
atrial fibrillation (AF) initiation or control. 
While VNS might be inefficient at high 
intensities, low-level VNS below the needed 
threshold to reduce heart rate, is effective in 
suppressing AF induction in anesthetized 
dogs. 
Table 2: VNS effects when applied to HF. 
 
In parallel to VNS through implantable devices, transcutaneous VNS (tVNS) has been proposed 
as an alternative approach (Ellrich, 2011, Kreuzer et al., 2012, Kampusch et al., 2013). Few 
studies have been conducted for the treatment of cardiac diseases by tVNS	 (Zamotrinsky et al., 
2001, Yu et al., 2013, Clancy et al., 2014, Wang et al., 2014a, Wang et al., 2014b, Ay et al., 
2015, Stavrakis et al., 2015, Wang et al., 2015a, Wang et al., 2015c, Wang et al., 2015b, Zhou et 
al., 2016). 
 
3.2	Existing	implantable	devices	for	weight	control	
 
Nowadays treatment options for obesity remain limited. These include diets, exercise programs, 
drugs, and bariatric surgery. Surgery is a frequent option because of its short- and long-term 
efficiency but it is limited to patients meeting the criterion of a body mass index (BMI) greater 
than 40 kg/m² or greater than to 35kg/m² with severe comorbidities. Moreover, bariatric surgery 
carries the risk of serious side effects such as long-term nutritional deficiencies and surgical 
complications. As these techniques focus on the gastrointestinal tract and caloric reduction, VNS 
may be a valuable alternative. 
Vagotomy has historically been a therapy for ulcer. Studies on patients with vagotomy have 
shown short-term weight loss, with some patients presenting prolonged loss of weight and 
appetite (Gortz et al., 1990). Based on these observations and trials of bilateral vagotomy as a 
treatment for obesity (Camilleri et al., 2008, Kral et al., 2009) – even though the results were 
mitigated – Enteromedics developed a device to induce weight loss. This device induces the 
blockade of the VN and the technique is called VBLOC therapy. The device is laparoscopically 
implanted. The stimulator is transcutaneously rechargeable and placed subcutaneously on the 
thoracic sidewall. Enteromedics received FDA approval in 2014. Other companies (e.g., abiliti® 
device, IntraPace Inc., San Jose, USA) are working on gastric electrical stimulation (GES) to 
induce the pacing of gastric contractions. GES causes early satiety and a sensation of fullness, 
mimicking the physiological signals the stomach sends to the brain when digesting food 
(Ladabaum et al., 1998, Chen, 2004). GES treatment for obesity began 20 years ago (Greenway 
and Zheng, 2007, Cha et al., 2014), and two studies (Table 3) have been conducted but without 
control groups. However, the authors compared the percentage of excess weight loss they 
observed with abiliti® (49.3%) to the gastric banding weight-loss efficacy range (35%). The 
presence of the intragastric sensor seemed to be well tolerated in both studies, but its invasiveness 
should be studied for longer periods to evaluate its effect on the stomach mucosa, particularly 
regarding infection or inflammation. One advantage of the technique is that the surgery required 
for the implantation is less invasive than bariatric surgery and leads to fewer complications. An 
earlier GES system (Transcend, Transneuronix, Medtronic in 2005) was placed by laparoscopy, 6 
cm from the pylorus and 3 cm from the edge of the lesser gastric curvature, below the “goose 
foot.” The study (Table 3) concluded that the effect was similar to that of other noninvasive 
techniques but that more research was needed to ensure that weight loss would be durable and to 
compare the efficacy against a control group. A clinical study is currently ongoing with the 
implantable GES Exilis (Medtronic), but data are not yet available (clinicaltrials.gov 
#NCT01823705) (Abell et al., 2015). 
The Tantalus Diamond (Metacure, Kfar-Saba, Israel) stimulates the gastric antrum when food 
enters the stomach (Mizrahi et al., 2012). Weight loss and glycemic control were shown in two 
studies (Table 3); however, in Sanmiguel et al., the weight loss was not correlated with the 
improved glucose control (Sanmiguel et al., 2009). Based on these analyses, it appears that the 
system induces moderate weight loss in diabetic patients, although the device has an effect on 
glucose metabolism. The Tantalus Diamond device obtained the CE mark in January 2007. 
 
Study Stimulation paradigm Main results 
Enteromedics system 
EMPOWER 
(Sarr et al., 2012)  
2 electrodes placed on the anterior and 
posterior VN at the gastroesophageal 
junction. 
Biphasic pulses, 5kHz, 3 to 8 mA, 5 minutes 
ON, 5 minutes OFF, delivering stimuli for 9 
to 16 hours per day. 
VBLOC therapy (blockade of VN). 
 
Weight loss but no significant effect of 
VBLOC therapy between the sham group and 
“blocked” group maybe biased by device 
checkups that needs activation. 
A subgroup analysis revealed a strong 
correlation between the improved excess 
weight loss and the hours of use of the 
stimulator. An important excess weight loss 
was obtained compared to controls with a use 
superior to 12 hours per day. 
Enteromedics system 
Clinical study 1 
(Ikramuddin et al., 2014)  
Clinical study 2 
(Shikora et al., 2013) 
Same as above but for sham n o stimulation 
occurred. 
239 participants with a BMI range of 35 to 45 
kg/m² for study 1 
 
12-month clinical study 2 on obese patients 
with type 2 diabetes mellitus 
  
Demonstration of efficacy of the therapy and 
safety of the device 
Weight loss was statistically more important 
in the vagal block group than in the sham 
group. 
At 12 months, the “VN blocked” group 
presented a 24.4% of excess weight loss vs. 
15.9% in the sham group. 
The co-primary objective not reached: mean 
percentage weight loss superior by a 10-point 
target to the sham group with at least 55% of 
patients in the “VN blocked” group achieving 
20% loss and 45% achieving a 25% loss. 
Adverse events rate was 3.7%. The primary 
safety objective was reached: rate of serious 
adverse events inferior to 15%. 
The most common adverse event for both 
groups was pain at the neuroregulator site. 
Adverse events recorded as mild or moderate 
for the “VN blocked” group only were: 
heartburn and dyspepsia, pain, dysphagia, 
nausea. Those adverse events were less severe 
than those found with bariatric surgery. 
 
The study 2 revealed VBLOC therapy as safe 
and efficient. 
Patients had a significant and sustained 
excess weight loss of 25%. 
Rapid and significant effect on glycemic 
control and blood pressure. 
abiliti® device, IntraPace 
(Ladabaum et al., 1998, Chen, 2004) 
(Greenway and Zheng, 2007, Cha et al., 
2014) 
Clinical studies 
(Horbach et al., 2015, Miras et al., 2015)  
GES 
2 electrodes placed on the serosa of the 
proximal stomach. 
Food sensor, transgastric electrode, is placed 
through the stomach gastric wall: the 
stimulation is meal-activated 
The stimulation electrode is implanted on the 
anterior wall of the stomach. 
An accelerometer records patient’s activity.  
Stimulation parameters: 4 to 30 mA, 100 – 
2000µs pulse duration, 40 – 120Hz. 
34 obese patients. 
The follow-up was carried out at 12 months 
and 27 months. 
Mean excess weight loss of 28.7% at 12 
months and of 27.5% at 27 months. 
Stable effect of weight loss overtime. 
Analysis of questionnaires reveals that 
patients improve their eating behavior as well 
as their QOL.  
Feedback on exercise and food intake 
recorded by the intragastric sensor is 
described as important to induce those 
changes in behaviors. 
Patients underwent gastro-endoscopic 
examinations to ensure that there was no 
problem with the intragastric probe.  
 
 
abiliti® device, IntraPace 
(Miras et al., 2015) 
Same as above 
27 obese patients with BMI 30 to 46 kg/m² 
49.3% excess weight loss at 12 months with 
no significant difference between age and 
gender. 
Using a subgroup analysis they showed that 
stimulation was more effective for patients 
with a lower BMI (30-40 kg/m²) than for 
those with a higher BMI. 
No adverse effects, but some patients felt 
mild stomach cramping during stimulation. 
These patients underwent a reprogramming of 
their stimulation parameters that led to the 
disappearance of those symptoms. 
Transcend, Transneuronix acquired by 
Medtronic in 2005 
(Favretti et al., 2004) 
GES 
20 morbid obese patients 
1 electrode placed in the gastric muscular 
wall of the stomach. 
Stimulation parameters used were the 
following: 10mA, 208µs for pulse width, 40 
Hz, 2 seconds ON and 3 seconds OFF 
effect on weight loss: after 1 month a 10.6% 
excess weight loss was observed reaching 
23.8% at 10 months. 
No serious complications were recorded. 
Tantalus Diamond (Metacure, Kfar-Saba, 
Israel) 
(Mizrahi et al., 2012) 
(Sanmiguel et al., 2009) 
Clinical studies 
(Bohdjalian et al., 2006, Lebovitz et al., 2013) 
Electrical stimulation of the gastric antrum 
when food is ingested in the stomach. 
3 sets of bipolar electrodes that are placed in 
the gastric wall: one used as a sensor in the 
gastric fundus, two used for stimulation meal-
activated. 
Stimulation parameters: biphasic symmetric, 
therapy delivered for approximately 75 
minutes (depending on patients) starting at 
the onset of a meal, 0.5 to 15 mA (depending 
on the patient’s feeling), 6 ms phase duration, 
1,200 ms for pulse duration, 83 Hz 
12 obese subjects for the first study. 
Bohdjalian et al. shows an excess weight loss 
of 30.5% at 52 weeks. 
Both showed an improvement of glycemic 
control and a modest weight loss in patients 
with Type 2 diabetes at 12 months for the 
second study.  
Table 3: studies about weight loss. 
 
4	Recent	scientific	and	technological	breakthroughs	
 
The main limitations of VNS for either obesity or HF are its therapeutic efficacy, which concerns 
the optimal delivery of the stimulation, and its side effects, which suggest the need for selective 
stimulation. The medical devices currently in use are based on classic stimulation paradigms, 
with rectangular pulses with fixed parameters delivered on a bipolar or tripolar cuff electrode. 
Selective stimulation, VN activity recordings and closed-loop control of the stimulation 
parameters are some of the recent breakthroughs that, although not yet confirmed by large 
clinical studies, may drive the next-generation designs of medical devices. Plachta et al. (Plachta 
et al., 2014) described a very good example of such advances, in which selective stimulation and 
VN recordings together with an innovative multicontact electrode design led not only to the 
ability to modulate blood pressure without many side effects, but also to the selective recording 
of the baroreceptor synchronous activity. 
 
4.1	Selectivity	and	efficiency	
 
There are two types of efferent cardioinhibitory fibers in the VN, namely small myelinated B (or 
Aδ) fibers and non-myelinated C fibers (Jones et al., 1998). However, there is a high number of 
other fibers in the VN and their activation may cause side effects. In particular, activation of 
afferent A fibers has been implicated in seizure suppression in anti-epileptic VNS (Anholt et al., 
2011), but activation of the A fibers branching to the laryngeal nerves leads to hoarseness. Thus, 
optimized VNS would selectively activate only a specified population of nerve fibers. Yet 
carrying out this task is difficult, because the thresholds for activation of B and C fibers are 
approximately 2-3 and 10-100 times greater, respectively, than the threshold of A fibers (Castoro 
et al., 2011). Nowadays, it seems impossible to activate C fibers at very high-level electrical 
stimulation without causing side effects. Therefore, most of the research related to VNS in 
cardiac applications aims at selective activation of B or even C fibers with low activation of A 
fibers (Castoro et al., 2011, Anholt et al., 2011). A few approaches to solve this problem may be 
distinguished. 
 
Minimizing charge required for activating B and C fibers using rectangular pulses, while 
minimizing side effects 
 
This approach also minimizes both the risk of tissue damage and the energy requirements. 
Castoro et al. investigated the influence of various pulse widths and amplitudes, as well as two 
waveforms (monophasic vs. asymmetric charge-balanced biphasic) and three electrode 
configurations (monopolar cathode, bipolar with cathode proximally, and bipolar with cathode 
distally) on the recruitment of the A, B and C fibers in the right VN of the dog (Castoro et al., 
2011). They concluded that neither the electrode configuration nor the stimulation waveform 
affected the recruitment of the different components of the compound action potential (CAP) and 
that pulse width had little influence on the normalized dynamic range of activation of A and B 
fibers. They also estimated that a 180-µs pulse width would allow activation of B fibers (but also 
A fibers) with the least amount of electrical charge. 
 
Modifying pulse shape in a way allowing for preferential activation of small fibers 
 
Quite a few techniques have been suggested for this purpose – for example, anodal block, high-
frequency block, slowly rising pulses, and depolarizing prepulses. However, their effectiveness 
has usually been shown on peripheral nerves, which contain much fewer fibers compared with 
the VN trunk. Vuckovic et al. investigated three of these techniques (anodal block, slowly rising 
pulses, and depolarizing prepulses) in pig VN (Vuckovic et al., 2008). Suppression of the greatest 
fiber activity (expressed as a percentage of the maximum response) was 0-40% for anodal block, 
10-25% for depolarizing prepulses and 40-50% for slowly rising pulses (with duration up to 5 
ms). The incomplete suppression of activation was mainly attributed to the large size of the VN 
trunk (3.0-3.5 mm), which resulted in a great difference in the excitation thresholds of nerve 
fibers at different distances from the electrode, as well as the relatively short duration of the 
slowly rising pulses. The techniques of slowly rising pulses and anodal block required 
comparable charges per phase, which were larger than for the technique of depolarizing prepulses 
and which exceeded the safety limits. Depolarizing prepulses were an optimal choice regarding 
the maximum required current and charge per phase, but were very sensitive to small changes in 
the current amplitude. Recently Irazoqui’s team proposed the use of either chopped square pulses 
or doublets (Qing et al., 2015). They showed that C fibers could be elicited with half the charge 
needed with classical rectangular pulses with a relative decrease of about 10% of the activation of 
A fibers in a rat VN. This technique should be confirmed but may make it easier to elicit C fibers 
with an increase in selectivity – that is, a larger threshold difference. 
To our knowledge, no one has thus far tested the application of the high-frequency conduction 
block for VNS. This is probably because of the issue of the onset response at the start of the 
stimulation, which would most likely cause a strong side effect. 
 
Modifying the electrode allowing preferential activation of the efferent fibers 
 
The rationale for doing so is that most undesired adverse effects during VNS for HF and obesity 
are caused by the activation of the afferent A fibers. This can be achieved by modifying the 
anodal block technique in which an asymmetrical cuff electrode is used. Such an approach is 
used in the CardioFit system (BioControl Medical Ltd, Yehudi, Israel), which is currently 
undergoing a multicenter randomized clinical trial (INOVATE-HF) (Hauptman et al., 2012); the 
clinical results have been discussed previously in (Gold et al., 2016). The effectiveness of this 
technique can possibly be further improved if quasi-trapezoid pulses are used (van den Honert 
and Mortimer, 1981). Using charge-balanced quasi-trapezoidal pulses driven through the 
CardioFit electrode (CSL), 63±13% unidirectional attenuation of the A fiber CAP was achieved 
in eight out of nine pigs (Anholt et al., 2011). 
 
Application of multi-contact electrode to preferentially activate fibers in a targeted region of the 
nerve, so called spatial selectivity 
 
To our knowledge, so far only Ordelman et al. (Ordelman, 2012, Ordelman et al., 2013) and 
Plachta et al. (Plachta et al., 2014) have investigated the use of this technique for VNS. Ordelman 
et al. compared bipolar stimulation in a single nerve cross-section using a multicontact cuff 
versus a tripolar ring electrode. Both types of cuff electrodes were compared with respect to their 
relative effects on the R-R interval (RRI), P-Q interval (PQI), left ventricular contractility (LVC) 
and left ventricular pressure (PLV) in seven pigs. Stimulation using the optimal bipolar 
configuration on the multicontact cuff significantly affected RRI, PQI, LVC and PLV, whereas 
stimulation with the ring electrode significantly affected only RRI and PQI. The cardiovascular 
parameters that could be significantly influenced varied between the bipolar configurations 
(Ordelman et al., 2013). These authors also observed in a similar experiment in awake pigs that 
the stimulation threshold for side effect was significantly higher with the multicontact cuff than 
with the ring electrode (Ordelman, 2012). Plachta et al. showed that longitudinal tripolar 
configurations for stimulation were able to limit side effects on bradycardia and bradypnea, 
whereas they had an action on blood pressure down to 60% in five rats (Plachta et al., 2014). 
They showed that selective VNS with longitudinal tripolar configurations was able to lower 
blood pressure and heart rate in an intensity- and pulse width- (with less homogeneity) dependent 
manner(Gierthmuehlen and Plachta, 2016). They concluded that baroreflex modulation with the 
combined effects of VNS and metoprolol medication was effective and still safe concerning 
bradycardia. 
 
Selectivity in gastric applications 
 
According to Hoffman (Hoffman and Schnitzlein, 1961), at least 97% of the nerve fibers in the 
esophageal plexus are C fibers, with the remaining 3% being myelinated Aδ or B fibers. Since 
the esophageal plexus later forms the anterior and posterior gastric nerves (ventral and dorsal 
vagal trunks) supplying all abdominal organs and the gastrointestinal tract, it seems that it is 
mostly the C fibers in the VN that influence gastric function. It is therefore reasonable to target 
the C fibers, although this requires high currents, which may cause adverse effects. It should also 
be kept in mind that visceral primary afferent fibers may be unmyelinated peripherally and 
myelinated more centrally (but distal to the soma) (Duclaux et al., 1976). 
In order to avoid activating the fibers innervating heart and lungs, in most cases the stimulation is 
delivered to the ventral and/or dorsal vagal trunk close to the esophagogastric junction (Camilleri 
et al., 2009, Val-Laillet et al., 2010b) – that is, below the place where the cardiac and pulmonary 
branches leave the VN. 
There may be, however, two distinct objectives of C fiber stimulation: 
• In most works and the 14 other publications listed in Table 1 of (Val-Laillet et al., 2010a) ), 
the objective was to activate the ascending C fibers in order to reduce appetite and induce a 
feeling of satiety. Although weight loss was observed in these cases, it is questionable 
whether the C fibers were activated, since Castoro et al. (Castoro et al., 2011) reported that 
the threshold for C fiber activation in the right VN of dog was 28 mA with a 300-µs pulse 
width, whereas in the studies reported by Val-Laillet much lower charges were used. For 
example, (Pardo et al., 2007) used pulses of 0.25-1.50 mA and 0.25-0.50 ms, and (Matyja et 
al., 2004) applied pulses with pulse widths of 170 mV and 170 ms. 
• Conversely, the objective of the VBLOC therapy is to block propagation of action potentials 
in Aδ and C fibers (Camilleri et al., 2009). Therefore, stimulation using a 5-kHz waveform 
of 1-6 mA amplitude was performed. It is nevertheless not clear whether this therapy was 
effective because the signals ascending to the brain were blocked or because the signals 
descending to the stomach, liver, pancreas, and small intestine were blocked (Richards, 
2009). Furthermore, it is not even sure whether the propagation of action potentials in the C 
fibers was blocked at all, since (Waataja et al., 2011) reported that when a similar waveform 
was used in the rat VN, 50% attenuation of C wave was achieved between 7 and 7.5 mA 
(50% blockade of the Aδ fibers was obtained between 2 and 3 mA). The results of 
EMPOWER, a randomized, double-blind, prospective study, showed that VBLOC 
stimulation was not more effective in obtaining excess weight loss than stimulation 
performed in the control group, which was stimulated with a much lower charge (less than 
1,000th of the charge delivered in the treated group) (Sarr et al., 2012). 
Thus, although various selective VNS strategies have been proposed for weight reduction, it is 
not clear which fibers are activated when they are applied and what the associated mechanism is. 
4.2	Closed	loop	control	in	HF	
 
The VNS devices used in the major clinical trials for HF (INOVATE-HF, NECTAR-HF, 
ANTHEM-HF) do not integrate any system for the automatic adaptation of stimulation 
parameters. However, the device used in the INOVATE-HF study (Schwartz and De Ferrari, 
2009) – that is, the Cardiofit system (BioControl Medical Ltd, Yehudi, Israel) – was designed to 
sense the heart rate (via an implanted intracardiac electrode) to deliver stimulation at preset 
delays from the R-wave. In order to avoid VNS-induced bradycardia, the stimulation is 
interrupted when heart rate drops below 55 bpm (De Ferrari et al., 2011). Nevertheless, this 
device does not include a cardiac stimulation feature, which would preserve cardiac function in 
the case of strong bradycardia. Conversely, the Equilia system (Sorin Group Italia, Saluggia, 
Italy) has a function to stimulate the heart in cases of bradycardia under a programmable value 
(VANGUARD trial, clinicaltrials.gov: NCT02113033). Other than this basic closed-loop 
function for avoiding severe bradycardia, there are currently no other implantable systems 
integrating closed-loop VNS control using cardiovascular signals as control variables. 
To our knowledge, the first attempt at a closed-loop VNS approach was proposed by Bilgutay et 
al. (Bilgutay et al., 1968). In their paper, three models of “vagal tuners” were proposed. Two of 
them were based on implantable devices that were manually activated. The third was an external 
device, which was automatically activated when the RR interval fell below a threshold value. In 
such vagal tuners, VNS is delivered synchronously with the R-wave, detected from the ECG 
signal. Although the two manual approaches were developed and evaluated on ten dogs, no 
details were given on the development or evaluation of the automatic approach. Two closed-loop 
systems for VNS control, based on the adaptation of the VNS frequency, have been proposed 
(Waninger et al., 2000). A control system, based on the cumulative sum control chart technique, 
adjusted the stimulation frequency in order to regulate the average ventricular rate during atrial 
fibrillation in dogs (Waninger et al., 2000). VNS was delivered continuously to the left VN, 
without any cardiac beat synchronization. Initially, the stimulation was delivered at a nominal 
frequency of 1 pulse/s and then the controller automatically updated the left VNS frequency. The 
other stimulation parameters were manually defined and fixed during the entire test for each dog 
(pulse width = 1 ms and current = 2-5 mA). Tosato et al. (Tosato et al., 2006) used a 
proportional-integral (PI) controller, which adjusted the stimulation frequency, in order to 
regulate heart rate in pigs. In their work, different tests were presented, including the stimulation 
of the left, right and both VNs. For each test, a different stimulation amplitude was kept constant 
in the range of 4-15 mA, the pulse width was fixed to 0.3 ms and the controller automatically 
updated the “optimal” stimulation frequency within the range of 0-20 Hz in three pigs and 0-2 Hz 
in four pigs. The update rate of the controller was kept constant within a test, but varied for each 
test within 10-60 updates/s and the stimulation was delivered asynchronously. In the system 
proposed by Zhang et al. (Zhang et al., 2002), a PI controller was used to determine the 
instantaneous amplitude of the impulses applied for VNS. This closed-loop system was used to 
determine the hemodynamic changes at each level of ventricular rate and to establish the optimal 
anterograde ventricular rate during atrial fibrillation. More recently, a VNS closed-loop control 
system was proposed in order to regulate the heart rate of a sheep with induced HF on a beat-to-
beat basis (Ugalde et al., 2014), but due to hardware constraints of the neuromodulator, only an 
on-off approach was implemented. The experimental results confirmed that the closed-loop VNS 
with the tested parameter configurations significantly modified the spontaneous RR interval. 
Nevertheless, the results showed significant RR oscillations, inherent to the on-off algorithm. 
Further works of the same group were directed toward implementing a more advanced control 
algorithm (PI controller) that effectively reduced these unwanted oscillations (Romero Ugalde et 
al., 2015). However, this approach has been limited to experimental studies, since this kind of 
controller is still too complex to be embedded in an implantable system.  
It should be noted that most published VNS control approaches have been limited to the 
modulation of only one stimulation parameter (often the current amplitude). The influence of all 
other VNS parameters has thus not been exploited, although it has been shown that different 
combinations of VNS settings are associated with a large variety of autonomic responses and 
may lead to an improved response while minimizing side effects (Rousselet et al., 2014). The 
future of embedded closed-loop VNS thus relies on the development of novel, lightweight 
methods allowing modulation of the different VNS parameters as a function of a set of 
physiological or physical variables acquired by the device. 
4.3	VN	activity	monitoring	
 
The information traveling along the VN is deeply mixed as it comes from various sources. 
Consequently, multicontact recordings together with dedicated signal processing to extract the 
valuable pieces of information linked particularly to cardiac activity have been investigated in 
only a few studies. Neural recordings in peripheral nerves are typically in the range of a few μV 
(Nikolić et al., 1994) and remain challenging. However, electroneurogram (ENG) signals from 
the VN recorded with chronically implanted cuff electrodes can be used to predict epileptic 
seizures	 (Nielsen et al., 2008). Several authors have therefore identified either manually or 
automatically the recorded single contact signal that was most correlated with the targeted 
activity. In Plachta et al. (Plachta et al., 2012, Plachta et al., 2014), the baroreceptor compound 
activity was detected using multichannel cuff electrode recordings on rat vagal nerve. Performing 
coherent averaging evidenced the activity. In (Rozman and Ribarič, 2007), the single-channel 
channel that was best correlated with heart activity was identified using the spectrum estimation 
technique. In (Peclin and Rozman, 2014), electrically evoked CAPs were measured in an isolated 
segment of porcine cervical left VN with a 9x11 multicontact cuff (MCC) electrode. The authors 
managed to achieve fiber selectivity through VNS parameters and demonstrated fascicle 
discrimination during neural response recording. 
Another option consists of combining the different electrode channels from an MCC electrode to 
create a virtual channel with enhanced characteristics. This decomposition can be archived using 
either data-driven approaches	 (Tesfayesus and Durand, 2007) that are based on the ENG signal 
statistics or inverse problem approaches. 
Concerning data-driven approaches, (Cheng et al., 2005) applied principal component analysis on 
4-channel bipolar recordings to estimate peroneal and tibial afferent activity in the sciatic nerve. 
In investigations on the same problematic, independent component analysis (ICA) was applied in 
(Tesfayesus and Durand, 2005, Tesfayesus and Durand, 2007) with the use of the FastICA 
algorithm: the influence of the number of sources and the permutation ambiguity inherent to ICA 
were addressed in these papers. 
The identification of the neural activity of different fascicles within a nerve from the global 
activity of the nerve through MCC electrodes has been investigated by two main research teams: 
that of Popovic, Univ. of Aalborg and Univ. of Belgrade, and that of Durand, Univ. of Cleveland. 
For instance, Zariffa et al. identified nerve activation using a computational forward model 
simple enough to allow real-time processing (Zariffa, Nagai et al. 2011). They managed to 
localize active pathways with mean localization errors in the 150-180 µm range (in a 720-µm 
diameter endoneurium, with 10-µm diameter individual fibers). However, the method suffered 
from numerous spurious pathways at moderately low noise levels (20% additive noise). 
The inverse problem is complex since the data are insufficient to identify a single source 
distribution. Moreover, the signal is corrupted by both exogenous and biological noise that is 
difficult to identify and model, and finally the inverse problem is ill-posed. Small errors may 
considerably hamper the estimation, and regularization methods should be used (Zariffa and 
Popovic, 2009). Hence computational methods developed for brain imaging have found their way 
to peripheral nerve imaging (Tesfayesus et al., 2004, Tesfayesus and Durand, 2005). Zariffa 
proposed to localize active pathways in peripheral nerves using the sLORETA method (Zariffa et 
al., 2009} while Wodlinger used a beamforming approach for the same task (Wodlinger and 
Durand, 2009). Rieger et al. tried to increase the information rate by using a MCC associated 
with velocity-selective recordings (VSR) (Rieger et al., 2004, Rieger and Taylor, 2013). In VSR, 
a series of ring electrodes are positioned in the longitudinal direction of the nerve. The different 
pieces of information along the nerve are combined using delay-and-add signal techniques that 
filter signals depending on their propagation velocity and direction. In Yoshida and Horch, a 
MCC was used to record two types of elicited single-fiber action potentials (SFAPs) in an 
earthworm model: 14.9 m/s and 6.9 m/s (Yoshida and Horch, 1996).  
4.4	Technology	
 
Electrode design 
 
The electrode is critical to measuring the ENG/CAP or applying neural stimulation. Neural 
electrodes can be placed either outside the nerve or intrafascicularly (penetrating the nerve, Table 
4). Cuff electrodes present conductive contacts embedded in an insulating tube that surrounds the 
nerve. Multicontact electrode cuffs enable selective stimulation or measurement. Increasing the 
number of contacts and decreasing their size provides better spatial resolution and consequently 
improves the selectivity (Grill and Mortimer, 1996) both for recordings and stimulation. The cuff 
electrodes record ENG/CAP and do not allow access to SFAP, contrary to intrafascicular 
electrodes. 
Type Features Description 
Flat interface nerve electrode (FINE) 
(Tyler and Durand, 2002) 
Multi contact cuff, Silicone, Pt contact The purpose is to flatten the nerve, for 
increasing its surface. So the distance 
between electrodes and fascicles is reduced, 
allowing a closer access to the fascicles 
Utah array (BlackRock) Intrafascicular electrodes up to 128 contacts penetrate into a nerve fascicle and enable 
selective activation of nerves .This type of 
electrode would enable more selective 
activation, due to the short distance between 
the contact and the fiber. 
TIME 
(Maciejasz et al., 2013, Boretius et al., 2010) 
LIFE 
(Yoshida and Horch, 1993, Djilas et al., 2009) 
(Badia et al., 2011) 
Up to 16 contacts inserted transversally 
within the nerve, Polyimide, IrOx contacts 
Typically 8 contacts inserted longitudinally 
within the nerve, Pt contacts 
TIME May stimulate individual fascicles 
Badia et al. shows differences between LIFE 
TIME and cuff regarding selectivity. LIFE is 
well suited for recording along few axons. 
Table 4: non conventional types of electrodes for peripheral nerve stimulation 
The VN is one of the most important cranial nerves; damage can result in permanent voice 
changes, a defect in cardiac rhythm and breathing difficulties. Less invasive interfaces like cuff 
electrodes thus remain the best solution compared with intrafascicular electrodes or those that 
change the nerve shape like the FINE (Table 4). Flexible cuffs do not compress the nerve, thus 
minimal fibrosis and trauma appear (Rodriguez et al., 2000). For ENG recordings, the tripolar 
configuration is used to reject noise (Stein et al., 1975); associated with a differential amplifier, 
the common mode (artifacts from far-field signals like EMG ECG) is rejected. For VN 
stimulation and recording, (Ordelman, 2012, Ordelman et al., 2013) and (Plachta et al., 2014) 
used MCC to achieve spatial selectivity for both VN stimulation or recording. 
For VNS applications, commercial electrodes are from Cyberonics (Houston, TX, USA): the 
helical electrodes are made of platinum ribbon with an open helical design. The electrodes are 
composed of three helical parts: one for cathode, one for anode, and one for anchoring (Amar et 
al., 2008). The electrode configuration is bipolar or tripolar. With a good seal, the cuff provides 
efficient stimulation by confining the stimulation current to the inner space of the electrode and 
avoiding current leak and crosstalk with other nerves and surrounding tissues (Loeb and Peck, 
1996). However, for helical structures, its open shape explains its low selectivity (Agnew et al., 
1989).  
The contact impedance must be as low as possible to increase the signal to noise ratio (SNR). The 
choice of the material is critical; for instance, iridium oxide exhibits lower impedance than 
platinum. In addition, for stimulation, this material presents a much higher injection charge. Last, 
local amplification of the recording signal improves the SNR, using for example an RHA1016 
preamplifier (Intan Technologies, UT, USA) (Tang et al., 2014). 
The trend in neural electrical stimulation is toward systems with a high number of contacts to 
improve selectivity. The advantage of microelectrodes is their ability to stimulate a comparatively 
small volume of neural tissue and to record the ENG from a smaller population of fibers. MEMS 
technology combines high precision and small dimensions for the patterns and ensures good 
repeatability compared with the macroelectrodes manufactured manually. For measurement and 
stimulation, the variability of the impedance of the active area should be the smallest possible. 
Research groups have focused on flexible electrodes based on MEMS technology for less 
invasive approaches. The most frequently used polymer is polyimide (Rubehn and Stieglitz 2010, 
Plachta, Espinosa et al. 2012), which is well mastered and regularly used in MEMS technology. 
Polyimide can support temperatures up to 350°C. Parylene is qualified for long-term human 
implants (Rodger, Fong et al. 2008, Kuo, Kim et al. 2013) and it possesses lower moisture 
absorption than polyimide, but it cannot handle such high temperatures. SU8 (Altuna, Bellistri et 
al. 2013) and liquid crystal polymer (Lee, Seo et al. 2009, Lee, Jun et al. 2012) are known for 
very low water absorption. (Hess, Dunning et al. 2007) investigated a new polymer 
Avatrel™/polynorbornene to manufacture a multicontact FINE-type electrode. This polymer, 
with its lower moisture absorption than polyimide, can be spin-coated and the metal layer is 
obtained by the liftoff process. The patterning is not performed by plasma etching with laser 
(Henle, Raab et al. 2011). The short-term cytotoxicity testing suggests that this material may be 
biocompatible. 
A wide range of materials has been used for the active area, including stainless steel, tungsten, 
platinum, and platinum-iridium alloys. To increase the selectivity, the active surface decreases, 
which thus increases the charge density and impedance. Thus, new materials with higher 
injection charge limits and lower impedance have been investigated. The most popular ones are 
iridium oxide (Meyer et al., 2001, Soo Hyun et al., 2009), platinum, carbon nanotubes (Sauter-
Starace et al., 2009, Musa et al., 2012), poly (ethylenedioxythiophene) (PEDOT) (Khodagholy et 
al., 2013), diamond (Maybeck et al., 2014), titanium nitride (Weiland et al., 2002). Platinum, 
currently used in implantable device, offers a limited reversible CSC: about 50-350 µC/cm², the 
iridium oxide provides 1200-3300 µC/cm²	(Merrill et al., 2005). It is not easy to compare the 
results because of the dependence on stimulation parameters. The charge injection limit measured 
by (Weiland et al., 2002) was 0.87 mC/cm² for titanium nitride and 4mC/cm² for Iridium oxide. 
Packaging the flexible microelectrodes is also challenging, particularly with respect to wire 
bonding. For the fabrication of multichannel electrodes, multiple wires must be connected to 
small thin electrodes. Several packaging techniques have been reported: zero insertion force 
(Ziegler et al., 2006), the stud bump acting as rivet (Stieglitz et al., 2005), the ACF (Anisotropic 
Conductive Films) (Baek et al., 2011), commercial Merrill, two connectors (Omnetics 
Connectors Corporation, Minneapolis, USA), attached with conductive epoxy (Patrick et al., 
2010). As the number of interconnections increases, the individual wires are replaced by flat 
flexible cables (FFC). The ribbon cables are conformable, and allow a collective approach for the 
electrical packaging. 
The commercial electrodes are still mainly in silicone rubber with iridium platinum bulk. To 
improve the selectivity, the trend is toward MEMS electrodes with polymer substratum, but long-
term implantation should confirm that these technologies remain reliable and efficient. 
 
Multi synchronous output stimulator 
 
For closed-loop control, particularly for HF, implantable VNS stimulators must embed at least a 
sensing stage to monitor changes in cardiac electrical activity, an output stage for stimulus 
generation, and a processor to compute the control algorithm. Closed-loop control is often limited 
to on/off control of the stimulus generator (BioControl Medical Ltd, Yehudi, Israel), this latter 
delivering a preprogrammed stimulation profile. Advanced closed-loop control, as previously 
described, relies on dynamically (real-time) adapting the stimulus after computing the next set of 
stimulation parameters according to a given control law – that is, an algorithm. These parameters 
are usually the frequency, pulse width and amplitude of a stimulus waveform that is often limited 
to rectangular biphasic pulses on bipolar or tripolar electrodes. Indeed, few multipolar stimulators 
allow for the configuration and real-time control of simulation parameters using several channels 
independently (i.e., independent current sources and not a global or “multiplexed” source) and 
supplying complex stimulation profiles. To do so, the stimulus generator must be able to deal 
with 1) the configuration of electrodes in terms of active contacts and their polarity (anode, 
cathode, high impedance), defined channel by channel	 (Guilvard et al., 2012), or as a global 
“virtual” electrode	(Andreu et al., 2009), and 2) the configuration of the global current repartition 
between active poles ensuring current ratios on active poles so that the relative current 
distribution remains constant whatever the total injected current (Techer et al., 2004, Soulier et 
al., 2008, Guilvard et al., 2012, Liu et al., 2012). These are mandatory features when the aim is 
spatial and directional (multiple sources or sinks for field shaping) and fiber-type (current ratios) 
selective stimulation. 
Although the impact of a multipolar electrode configuration has been demonstrated in several 
studies	(Badia et al., 2011), no existing device to our knowledge allows for dynamically playing 
with the global electrode configuration, except to some extent the implantable versatile electrode-
driving ASIC which is an output stage, without the microcontroller, dedicated to epidural 
stimulation	 (Giagka et al., 2015). This drastically increases the stimulator complexity since it 
requires both dynamically modifying the electrode configuration and accurately and 
independently controlling the injection of charges on a subset of contacts. But this modifies the 
paradigm of VNS stimulation since being able to dynamically – or more precisely, sequentially 
(i.e., interleaved stimulation) – select the multipolar electrode configuration also allows for 
combining several stimulation physiological effects on heart rhythm (in addition to modulating 
the frequency or the injected quantity of charges). 
5	Conclusion	
 
Clearly, VNS has a huge potential to treat numerous diseases linked to the autonomous nervous 
system, as already demonstrated for weight control and HF. It is already a well-established 
technique for treating epilepsy and other pathologies related to brain functions that can be 
neuromodulated. However, in order to use effective, safe and robust VNS, several issues, indexed 
in this state-of-the-art review, still remain to be elucidated. Encouraging new techniques of 
stimulation and recordings should nevertheless drastically improve and broaden VNS 
applications in the near future. 
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